Allarity Therapeutics (ALLR) Institutional Ownership → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free ALLR Stock Alerts $0.67 -0.01 (-1.46%) (As of 05/16/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Allarity Therapeutics (NASDAQ:ALLR)CurrentInstitutional OwnershipPercentage11.53%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$9.27MNumber ofInstitutional Sellers(last 12 months)0 Get ALLR Insider Trade Alerts Want to know when executives and insiders are buying or selling Allarity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. Allarity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023 Sabby Management LLC359,400$268K0.2%N/A13.165% 11/15/2023 Armistice Capital LLC261,000$195K0.0%N/A9.560% (Data available from 1/1/2016 forward) ALLR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALLR shares? During the previous two years, the following institutional investors and hedge funds held shares of Allarity Therapeutics shares: Sabby Management LLC ($268K), Armistice Capital LLC ($195K).Learn more on ALLR's institutional investors. What percentage of Allarity Therapeutics stock is owned by institutional investors? 11.53% of Allarity Therapeutics stock is owned by institutional investors. Learn more on ALLR's institutional investor holdings. Which institutional investors have been buying Allarity Therapeutics stock? The following institutional investors have purchased Allarity Therapeutics stock in the last 24 months: Sabby Management LLC ($359.40K), and Armistice Capital LLC ($261K). How much institutional buying is happening at Allarity Therapeutics? Institutional investors have bought a total of 620,400 shares in the last 24 months. This purchase volume represents approximately $9.27M in transactions. Related Companies: Qualigen Therapeutics Major Shareholders PainReform Major Shareholders Galmed Pharmaceuticals Major Shareholders 180 Life Sciences Major Shareholders InMed Pharmaceuticals Major Shareholders CNS Pharmaceuticals Major Shareholders Clearmind Medicine Major Shareholders Dermata Therapeutics Major Shareholders Panbela Therapeutics Major Shareholders Altamira Therapeutics Major Shareholders This page (NASDAQ:ALLR) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.